Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

The BRCA gene encodes for the BRCA proteins, BRCA1 and BRCA2. These proteins are very important in repairing DNA, which they do by correcting double-stranded breaks. [More]
Prostate cancer discovery may improve treatment strategies

Prostate cancer discovery may improve treatment strategies

Scientists from Cancer Research UK have discovered that there are five different types of prostate cancer and have found a way of distinguishing between them. These findings could change how the condition is treated, providing more effective therapies where they are needed the most. [More]
Cancer Research UK scientists identify five distinct types of prostate cancer

Cancer Research UK scientists identify five distinct types of prostate cancer

Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine. [More]
Moffitt researchers analyze participation rate of patients in pharmacogenomic trials

Moffitt researchers analyze participation rate of patients in pharmacogenomic trials

Cancer therapy has evolved from a "one-size-fits-all" type of treatment plan to a personalized approach based on a patient's type of cancer, the protein and genetic markers found in their tumors and their response to therapy. Important aspects of the personalized approach are pharmacogenomic studies that analyze associations between genetic variations and patient drug responses. [More]
German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial. [More]
VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc., to support initial U.S. market entry of its NuQ colorectal cancer tests. [More]
ESSA Pharma receives final approval to start trading on Toronto Stock Exchange

ESSA Pharma receives final approval to start trading on Toronto Stock Exchange

ESSA Pharma Inc. is pleased to announce that it has received final approval for its common shares to be listed and commence trading on the Toronto Stock Exchange. [More]
Prostate cancer patients more likely to receive medical care matched to level of risk

Prostate cancer patients more likely to receive medical care matched to level of risk

After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, according to a study by researchers at UC San Francisco. [More]
Study analyzes effect of shift work on prostate cancer

Study analyzes effect of shift work on prostate cancer

In a recent original article in Deutsches Ärzteblatt International (Dtsch Arztbl Int 112: 463-70), Gael P. Hammer et al. show that shift workers do not develop prostate cancer more frequently than their colleagues who work during the day. [More]
York scientists identify how some micro-RNAs can make prostate cancers resistant to radiotherapy

York scientists identify how some micro-RNAs can make prostate cancers resistant to radiotherapy

Scientists at the University of York believe they have identified how some tiny regulatory molecules in cells can make prostate cancers resistant to radiotherapy. [More]
Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

The Endocrine Society today announced it has chosen 18 accomplished endocrinologists as winners of the organization's prestigious 2016 Laureate Awards. [More]
Gene responsible for cancer growth plays unexpected role in prostate cancer

Gene responsible for cancer growth plays unexpected role in prostate cancer

A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the Veterinary University of Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression. [More]
Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically significant increased risk, however a small increased risk could not be excluded, according to a study in the July 21 issue of JAMA. [More]
New genomic fingerprint may predict prostate cancer risk in African American men

New genomic fingerprint may predict prostate cancer risk in African American men

African American men are more likely to develop prostate cancer than European American men, and are also more than twice as likely to die from it. Although there are many reasons that contribute to this health disparity, new research shows that African American men may have a distinctly different type of prostate cancer than European American men, according to new genomic fingerprinting results. [More]
UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells

UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells

UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease. [More]
NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new tests include comprehensive testing for BRCA1 and BRCA2 encompassing an analysis of all exons and adjacent intronic regions. [More]
Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer, according to a new study from Penn Medicine published this week in JAMA Oncology. Already-high survival rates for men with low-risk prostate cancer were unaffected by higher radiation dosages compared to lower radiation dosages. [More]
Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma. [More]
Accuray announces presentation of CyberKnife System data at AAPM annual meeting

Accuray announces presentation of CyberKnife System data at AAPM annual meeting

Accuray Incorporated announced today that studies on the clinical use of the CyberKnife System, the only robotic SBRT system capable of tracking and automatically correcting for target motion, continue to demonstrate the benefits of its precise, innovative treatment delivery techniques. [More]
New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

Current U.S. Preventive Services Task Force Guidelines for prostate screening may be impacting the detection of high-risk prostate cancer. [More]
Advertisement